News

Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.

Please consider a small donation if you think this website provides you with relevant information  

   
Date Title Source
2023-04-16 9:50:24 pm Enlivex Therapeutics (ENLV) Investor Presentation - Slideshow SeekingAlpha
2023-04-14 6:40:0 am Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials ACCESSWIRE
2023-04-12 7:45:0 am Enlivex, Beigene Collaborate To Test A New Combination Treatment To Fight Advanced-Stage Solid Tumors ACCESSWIRE
2023-04-10 12:7:7 am BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains? Zacks
2023-04-04 5:0:0 am Enlivex Announces Tislelizumab Clinical Collaboration, Full Year 2022 Financial Results, and Provides Business Updates GlobeNewswire
2023-04-03 5:0:0 am Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra and PD-1 Inhibitor Tislelizumab for Patients with Solid Tumors GlobeNewswire
2023-03-20 5:0:0 am Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers GlobeNewswire
2023-02-23 5:0:0 am Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial GlobeNewswire
2023-02-15 5:0:0 am Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS GlobeNewswire
   

Please consider a small donation if you think this website provides you with relevant information